| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dendritic Cells | 16 | 2025 | 414 | 3.110 |
Why?
|
| Th1 Cells | 9 | 2025 | 153 | 2.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 9 | 2025 | 397 | 1.800 |
Why?
|
| Cancer Vaccines | 5 | 2021 | 177 | 1.490 |
Why?
|
| Tumor Microenvironment | 4 | 2025 | 557 | 1.470 |
Why?
|
| Immunologic Memory | 3 | 2021 | 190 | 1.360 |
Why?
|
| Cytokines | 4 | 2025 | 1288 | 1.250 |
Why?
|
| CTLA-4 Antigen | 2 | 2020 | 61 | 1.200 |
Why?
|
| Amino Acyl-tRNA Synthetases | 3 | 2024 | 26 | 1.150 |
Why?
|
| T-Lymphocytes, Cytotoxic | 6 | 2021 | 504 | 1.150 |
Why?
|
| Immunotherapy | 7 | 2019 | 680 | 1.090 |
Why?
|
| Neoplasms | 10 | 2025 | 2794 | 1.010 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2020 | 84 | 0.970 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2025 | 6 | 0.960 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2020 | 97 | 0.950 |
Why?
|
| Fetal Blood | 9 | 2013 | 176 | 0.950 |
Why?
|
| Adaptive Immunity | 2 | 2015 | 89 | 0.910 |
Why?
|
| T-Lymphocytes | 8 | 2020 | 1725 | 0.800 |
Why?
|
| Immunity, Innate | 2 | 2015 | 372 | 0.790 |
Why?
|
| Dog Diseases | 2 | 2020 | 50 | 0.770 |
Why?
|
| Homeostasis | 2 | 2024 | 703 | 0.740 |
Why?
|
| Receptors, IgG | 1 | 2021 | 59 | 0.700 |
Why?
|
| CD40 Antigens | 2 | 2012 | 26 | 0.700 |
Why?
|
| Immune System | 1 | 2020 | 90 | 0.670 |
Why?
|
| Immunity, Cellular | 2 | 2020 | 206 | 0.650 |
Why?
|
| Vaccination | 5 | 2019 | 963 | 0.650 |
Why?
|
| Animals | 37 | 2025 | 34219 | 0.630 |
Why?
|
| Hemangiosarcoma | 1 | 2019 | 41 | 0.610 |
Why?
|
| Doxorubicin | 1 | 2019 | 290 | 0.560 |
Why?
|
| Peptides | 3 | 2020 | 811 | 0.560 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2017 | 48 | 0.550 |
Why?
|
| Antigens, Neoplasm | 4 | 2025 | 386 | 0.540 |
Why?
|
| Neoplasm Proteins | 2 | 2025 | 668 | 0.540 |
Why?
|
| Bystander Effect | 1 | 2016 | 6 | 0.520 |
Why?
|
| B7 Antigens | 1 | 2016 | 9 | 0.520 |
Why?
|
| Antigen-Presenting Cells | 3 | 2013 | 118 | 0.510 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2017 | 164 | 0.500 |
Why?
|
| Porins | 6 | 2001 | 41 | 0.500 |
Why?
|
| Cytosol | 1 | 2015 | 162 | 0.480 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2015 | 52 | 0.480 |
Why?
|
| Mice | 26 | 2025 | 17632 | 0.440 |
Why?
|
| Immunomodulation | 2 | 2024 | 79 | 0.440 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 1026 | 0.430 |
Why?
|
| Mice, Inbred BALB C | 6 | 2020 | 998 | 0.420 |
Why?
|
| Interferon-gamma | 8 | 2017 | 506 | 0.420 |
Why?
|
| Stress, Physiological | 1 | 2015 | 254 | 0.400 |
Why?
|
| Vaccines | 1 | 2017 | 365 | 0.400 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2011 | 19 | 0.370 |
Why?
|
| AIDS Vaccines | 1 | 2011 | 30 | 0.370 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 573 | 0.360 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 183 | 0.360 |
Why?
|
| Humans | 43 | 2025 | 125138 | 0.330 |
Why?
|
| Th2 Cells | 2 | 2007 | 185 | 0.330 |
Why?
|
| Influenza Vaccines | 3 | 2012 | 481 | 0.330 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 382 | 0.320 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2025 | 350 | 0.320 |
Why?
|
| Killer Cells, Natural | 3 | 2021 | 330 | 0.320 |
Why?
|
| Mice, Inbred C57BL | 5 | 2024 | 4404 | 0.300 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 293 | 0.290 |
Why?
|
| Exotoxins | 1 | 2007 | 45 | 0.290 |
Why?
|
| Anthrax Vaccines | 1 | 2007 | 26 | 0.290 |
Why?
|
| Anthrax | 1 | 2007 | 31 | 0.280 |
Why?
|
| Influenza, Human | 2 | 2012 | 661 | 0.280 |
Why?
|
| Bacillus anthracis | 1 | 2007 | 40 | 0.280 |
Why?
|
| Communicable Diseases | 1 | 2009 | 160 | 0.270 |
Why?
|
| Cell Polarity | 1 | 2007 | 121 | 0.270 |
Why?
|
| Bacterial Toxins | 1 | 2007 | 175 | 0.270 |
Why?
|
| Plasmids | 1 | 2007 | 513 | 0.260 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2025 | 118 | 0.260 |
Why?
|
| Cells, Cultured | 8 | 2019 | 3054 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 683 | 0.250 |
Why?
|
| Antigens, Bacterial | 1 | 2007 | 314 | 0.250 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2025 | 115 | 0.240 |
Why?
|
| Vaccines, DNA | 1 | 2005 | 48 | 0.240 |
Why?
|
| Cell Line, Tumor | 5 | 2025 | 3348 | 0.240 |
Why?
|
| Antigens, CD34 | 6 | 2012 | 109 | 0.240 |
Why?
|
| RNA, Messenger | 3 | 2008 | 2821 | 0.230 |
Why?
|
| Plasma Cells | 1 | 2025 | 55 | 0.230 |
Why?
|
| Smoke | 1 | 2025 | 60 | 0.230 |
Why?
|
| Ion Channels | 4 | 1999 | 190 | 0.230 |
Why?
|
| Immunoassay | 1 | 2025 | 130 | 0.230 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2010 | 536 | 0.230 |
Why?
|
| Cell Differentiation | 2 | 2011 | 1896 | 0.230 |
Why?
|
| Antigens, CD | 6 | 2009 | 432 | 0.220 |
Why?
|
| Immunity | 1 | 2025 | 192 | 0.220 |
Why?
|
| Antibodies | 1 | 2005 | 374 | 0.220 |
Why?
|
| Cluster Analysis | 1 | 2025 | 398 | 0.220 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 3 | 2013 | 12 | 0.210 |
Why?
|
| Cell Proliferation | 5 | 2015 | 2312 | 0.210 |
Why?
|
| Lymphocyte Activation | 5 | 2009 | 701 | 0.210 |
Why?
|
| Lung Neoplasms | 2 | 2025 | 1660 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2021 | 327 | 0.200 |
Why?
|
| Glutathione Peroxidase | 1 | 2022 | 53 | 0.200 |
Why?
|
| Carcinogenesis | 2 | 2015 | 333 | 0.190 |
Why?
|
| Vaccines, Synthetic | 2 | 2017 | 316 | 0.190 |
Why?
|
| Sezary Syndrome | 2 | 2014 | 12 | 0.190 |
Why?
|
| Disease Models, Animal | 5 | 2020 | 4392 | 0.190 |
Why?
|
| Alternative Splicing | 3 | 2000 | 352 | 0.180 |
Why?
|
| Dogs | 2 | 2020 | 775 | 0.180 |
Why?
|
| Immunophenotyping | 3 | 2019 | 329 | 0.180 |
Why?
|
| Adenoviridae | 2 | 2017 | 604 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2025 | 1893 | 0.180 |
Why?
|
| Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2013 | 59 | 0.170 |
Why?
|
| Multiple Myeloma | 2 | 2013 | 170 | 0.170 |
Why?
|
| Cannabidiol | 1 | 2020 | 22 | 0.170 |
Why?
|
| Exons | 2 | 2000 | 798 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 1 | 2025 | 503 | 0.170 |
Why?
|
| Mitochondria, Muscle | 1 | 2000 | 34 | 0.170 |
Why?
|
| Arthralgia | 1 | 2020 | 55 | 0.170 |
Why?
|
| History, 19th Century | 2 | 2011 | 116 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 198 | 0.170 |
Why?
|
| Sensitivity and Specificity | 1 | 2025 | 2056 | 0.160 |
Why?
|
| Oxidative Stress | 1 | 2025 | 838 | 0.160 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 576 | 0.160 |
Why?
|
| Bone Marrow Purging | 2 | 2011 | 34 | 0.160 |
Why?
|
| Osteoarthritis | 1 | 2020 | 86 | 0.160 |
Why?
|
| Neuroblastoma | 1 | 2024 | 526 | 0.160 |
Why?
|
| Amino Acid Sequence | 4 | 2020 | 2715 | 0.150 |
Why?
|
| History, 20th Century | 2 | 2011 | 381 | 0.150 |
Why?
|
| Intracellular Space | 2 | 2016 | 49 | 0.150 |
Why?
|
| Monte Carlo Method | 1 | 2019 | 94 | 0.150 |
Why?
|
| Transduction, Genetic | 2 | 2017 | 289 | 0.150 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 250 | 0.150 |
Why?
|
| Macrophages | 2 | 2015 | 625 | 0.150 |
Why?
|
| Membrane Glycoproteins | 3 | 2012 | 411 | 0.150 |
Why?
|
| Reproducibility of Results | 1 | 2025 | 2892 | 0.150 |
Why?
|
| Interleukin-12 | 2 | 2009 | 116 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2017 | 472 | 0.140 |
Why?
|
| Prognosis | 2 | 2025 | 4642 | 0.140 |
Why?
|
| CD3 Complex | 4 | 2013 | 91 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2015 | 483 | 0.140 |
Why?
|
| Antigens, Protozoan | 1 | 2017 | 66 | 0.140 |
Why?
|
| Signal Transduction | 3 | 2020 | 4534 | 0.140 |
Why?
|
| Biomarkers, Tumor | 1 | 2025 | 1497 | 0.140 |
Why?
|
| Drug Carriers | 1 | 2017 | 100 | 0.140 |
Why?
|
| CD40 Ligand | 2 | 2007 | 64 | 0.130 |
Why?
|
| Antigen Presentation | 3 | 2015 | 104 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2011 | 540 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2015 | 218 | 0.130 |
Why?
|
| Voltage-Dependent Anion Channels | 6 | 2001 | 31 | 0.130 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 214 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 240 | 0.120 |
Why?
|
| Peptide Elongation Factors | 1 | 2015 | 12 | 0.120 |
Why?
|
| Cell Separation | 4 | 2011 | 228 | 0.120 |
Why?
|
| Monocytes | 2 | 2016 | 345 | 0.120 |
Why?
|
| Immunological Synapses | 2 | 2012 | 26 | 0.120 |
Why?
|
| Carcinogens, Environmental | 1 | 2015 | 16 | 0.120 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 55 | 0.120 |
Why?
|
| Hazardous Substances | 1 | 2015 | 17 | 0.120 |
Why?
|
| Female | 9 | 2024 | 66771 | 0.120 |
Why?
|
| Genetic Heterogeneity | 1 | 2015 | 125 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1241 | 0.120 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2015 | 3 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2015 | 468 | 0.120 |
Why?
|
| Dinoprostone | 2 | 2022 | 77 | 0.120 |
Why?
|
| Immune Evasion | 1 | 2015 | 35 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 359 | 0.120 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 2522 | 0.120 |
Why?
|
| Mycosis Fungoides | 1 | 2014 | 14 | 0.120 |
Why?
|
| Flow Cytometry | 4 | 2012 | 794 | 0.120 |
Why?
|
| Skin Neoplasms | 2 | 2014 | 862 | 0.110 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 662 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2017 | 1506 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2017 | 936 | 0.110 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2013 | 264 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 362 | 0.100 |
Why?
|
| Environmental Exposure | 1 | 2015 | 220 | 0.100 |
Why?
|
| Feasibility Studies | 2 | 2012 | 761 | 0.100 |
Why?
|
| Influenza in Birds | 1 | 2012 | 27 | 0.100 |
Why?
|
| Mitochondria | 5 | 2001 | 680 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2015 | 319 | 0.100 |
Why?
|
| Lipopolysaccharide Receptors | 2 | 2009 | 51 | 0.100 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2012 | 10 | 0.100 |
Why?
|
| Fucose | 1 | 2012 | 21 | 0.100 |
Why?
|
| Vaccines, Inactivated | 1 | 2012 | 145 | 0.100 |
Why?
|
| Protein Isoforms | 4 | 2001 | 404 | 0.100 |
Why?
|
| Influenza A virus | 1 | 2013 | 139 | 0.100 |
Why?
|
| Cell Movement | 1 | 2015 | 847 | 0.100 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2009 | 48 | 0.090 |
Why?
|
| Molecular Sequence Data | 6 | 2012 | 3891 | 0.090 |
Why?
|
| HLA Antigens | 1 | 2012 | 245 | 0.090 |
Why?
|
| History, 18th Century | 1 | 2011 | 70 | 0.090 |
Why?
|
| Protein Multimerization | 1 | 2012 | 128 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 63 | 0.090 |
Why?
|
| Boronic Acids | 1 | 2011 | 47 | 0.090 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 38 | 0.090 |
Why?
|
| Pyrazines | 1 | 2011 | 75 | 0.090 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2011 | 85 | 0.090 |
Why?
|
| Wnt Signaling Pathway | 1 | 2012 | 190 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 512 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2011 | 264 | 0.090 |
Why?
|
| Orthomyxoviridae | 1 | 2010 | 51 | 0.080 |
Why?
|
| Mice, SCID | 4 | 2013 | 569 | 0.080 |
Why?
|
| Transplantation, Autologous | 2 | 2011 | 299 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 306 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 1265 | 0.080 |
Why?
|
| Bone Marrow Cells | 2 | 2012 | 264 | 0.080 |
Why?
|
| Interleukin-6 | 2 | 2008 | 420 | 0.080 |
Why?
|
| Antigens, Viral | 1 | 2010 | 439 | 0.070 |
Why?
|
| Glycerol Kinase | 2 | 1999 | 19 | 0.070 |
Why?
|
| Immunoglobulins | 1 | 2009 | 173 | 0.070 |
Why?
|
| Langerhans Cells | 1 | 2008 | 19 | 0.070 |
Why?
|
| Inflammation | 1 | 2015 | 1447 | 0.070 |
Why?
|
| Transfection | 2 | 2008 | 1068 | 0.070 |
Why?
|
| K562 Cells | 3 | 2014 | 95 | 0.070 |
Why?
|
| Epitopes | 1 | 2009 | 433 | 0.070 |
Why?
|
| Interleukin-1beta | 1 | 2008 | 162 | 0.070 |
Why?
|
| Protein Subunits | 1 | 2007 | 165 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2014 | 1694 | 0.070 |
Why?
|
| Mice, Inbred NOD | 3 | 2013 | 286 | 0.070 |
Why?
|
| X Chromosome | 2 | 1999 | 338 | 0.070 |
Why?
|
| Species Specificity | 1 | 2007 | 550 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2008 | 174 | 0.070 |
Why?
|
| Myocardium | 1 | 2011 | 1016 | 0.060 |
Why?
|
| Evolution, Molecular | 2 | 1999 | 666 | 0.060 |
Why?
|
| Lymphocyte Subsets | 1 | 2006 | 38 | 0.060 |
Why?
|
| Herpesvirus 4, Human | 1 | 2009 | 676 | 0.060 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2006 | 79 | 0.060 |
Why?
|
| Toll-Like Receptors | 1 | 2006 | 84 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2006 | 97 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 1016 | 0.060 |
Why?
|
| Leukemia, Myeloid | 1 | 2006 | 85 | 0.060 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2005 | 48 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 108 | 0.060 |
Why?
|
| Neoplasm Transplantation | 1 | 2005 | 376 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2010 | 519 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2017 | 12392 | 0.060 |
Why?
|
| Male | 8 | 2021 | 61493 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 238 | 0.060 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2010 | 833 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 245 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 1043 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2102 | 0.050 |
Why?
|
| Epigenesis, Genetic | 1 | 2007 | 676 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 889 | 0.050 |
Why?
|
| Bacterial Proteins | 1 | 2007 | 890 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 1711 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1035 | 0.050 |
Why?
|
| Interleukin-2 | 2 | 2013 | 244 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 1101 | 0.050 |
Why?
|
| Base Sequence | 3 | 2000 | 3102 | 0.040 |
Why?
|
| Endothelial Cells | 2 | 2017 | 524 | 0.040 |
Why?
|
| Sperm Motility | 1 | 2001 | 95 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2005 | 813 | 0.040 |
Why?
|
| Cell Culture Techniques | 2 | 2013 | 281 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2014 | 74 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6600 | 0.040 |
Why?
|
| Cannabis | 1 | 2020 | 40 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2013 | 3744 | 0.040 |
Why?
|
| Cell Survival | 3 | 2011 | 813 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2000 | 289 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2021 | 281 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2000 | 204 | 0.040 |
Why?
|
| Coculture Techniques | 2 | 2013 | 226 | 0.040 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2000 | 61 | 0.040 |
Why?
|
| Biomarkers | 1 | 2009 | 3090 | 0.040 |
Why?
|
| Lod Score | 1 | 1999 | 120 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1999 | 64 | 0.040 |
Why?
|
| Retroelements | 1 | 1999 | 40 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1999 | 78 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2000 | 291 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 1999 | 1078 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 1999 | 120 | 0.040 |
Why?
|
| Cell Lineage | 2 | 2012 | 345 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2000 | 621 | 0.040 |
Why?
|
| Infertility, Male | 1 | 2001 | 263 | 0.040 |
Why?
|
| Genetic Linkage | 1 | 1999 | 453 | 0.040 |
Why?
|
| Genetic Markers | 1 | 1999 | 603 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 1398 | 0.030 |
Why?
|
| Pericytes | 1 | 2017 | 21 | 0.030 |
Why?
|
| Muscle, Skeletal | 2 | 2001 | 946 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 95 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2017 | 76 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 1638 | 0.030 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 3 | 2001 | 23 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 236 | 0.030 |
Why?
|
| Phytochemicals | 1 | 2015 | 8 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 101 | 0.030 |
Why?
|
| Receptors, CCR4 | 1 | 2014 | 7 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2015 | 62 | 0.030 |
Why?
|
| DNA | 1 | 2000 | 1608 | 0.030 |
Why?
|
| Adult | 2 | 2012 | 29634 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2015 | 144 | 0.030 |
Why?
|
| United States | 1 | 2009 | 10916 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2000 | 1755 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily D | 1 | 2013 | 1 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2013 | 3 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 2013 | 26 | 0.030 |
Why?
|
| Blotting, Western | 3 | 2001 | 1101 | 0.030 |
Why?
|
| Aged | 3 | 2021 | 19871 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2013 | 11 | 0.030 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 1 | 2012 | 11 | 0.030 |
Why?
|
| Influenza A Virus, H7N7 Subtype | 1 | 2012 | 11 | 0.030 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2013 | 59 | 0.030 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2012 | 114 | 0.030 |
Why?
|
| Birds | 1 | 2012 | 85 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 355 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 348 | 0.020 |
Why?
|
| Axin Protein | 1 | 2012 | 18 | 0.020 |
Why?
|
| Casein Kinase I | 1 | 2012 | 12 | 0.020 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2012 | 61 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2009 | 1695 | 0.020 |
Why?
|
| Dishevelled Proteins | 1 | 2012 | 43 | 0.020 |
Why?
|
| Arabinofuranosyluracil | 1 | 2011 | 4 | 0.020 |
Why?
|
| Lymphography | 1 | 2011 | 12 | 0.020 |
Why?
|
| Middle Aged | 3 | 2021 | 26932 | 0.020 |
Why?
|
| Membrane Microdomains | 1 | 2012 | 61 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 2011 | 95 | 0.020 |
Why?
|
| Lymphatic Vessels | 1 | 2011 | 37 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2011 | 27 | 0.020 |
Why?
|
| Cell Line | 2 | 2011 | 2758 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 256 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 725 | 0.020 |
Why?
|
| Magnetics | 1 | 2011 | 41 | 0.020 |
Why?
|
| Bortezomib | 1 | 2011 | 72 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1998 | 1526 | 0.020 |
Why?
|
| Spleen | 1 | 2012 | 280 | 0.020 |
Why?
|
| CD2 Antigens | 1 | 2010 | 8 | 0.020 |
Why?
|
| Receptor Aggregation | 1 | 2010 | 7 | 0.020 |
Why?
|
| Perforin | 1 | 2010 | 17 | 0.020 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2012 | 139 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2010 | 30 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 368 | 0.020 |
Why?
|
| beta Catenin | 1 | 2012 | 204 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 581 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2011 | 381 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2012 | 302 | 0.020 |
Why?
|
| Rituximab | 1 | 2011 | 158 | 0.020 |
Why?
|
| Voltage-Dependent Anion Channel 2 | 2 | 1999 | 17 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2012 | 417 | 0.020 |
Why?
|
| Luciferases, Firefly | 1 | 2009 | 14 | 0.020 |
Why?
|
| Luminescent Agents | 1 | 2009 | 7 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2009 | 59 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2011 | 379 | 0.020 |
Why?
|
| Prostate | 1 | 2012 | 435 | 0.020 |
Why?
|
| Baculoviridae | 1 | 2009 | 64 | 0.020 |
Why?
|
| Culture Media | 1 | 2009 | 182 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2009 | 36 | 0.020 |
Why?
|
| Receptor, EphA4 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Granzymes | 1 | 2008 | 37 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 552 | 0.020 |
Why?
|
| Brain | 1 | 2000 | 2999 | 0.020 |
Why?
|
| Actins | 1 | 2010 | 346 | 0.020 |
Why?
|
| Twist-Related Protein 1 | 1 | 2008 | 35 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2008 | 45 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1631 | 0.020 |
Why?
|
| Swine | 1 | 2011 | 1207 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2009 | 216 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1757 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 5842 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2009 | 981 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2012 | 909 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 826 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 1999 | 462 | 0.020 |
Why?
|
| Neutrophils | 1 | 2009 | 381 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2009 | 327 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2012 | 1153 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2006 | 46 | 0.020 |
Why?
|
| AC133 Antigen | 1 | 2006 | 35 | 0.020 |
Why?
|
| Mothers | 1 | 2009 | 355 | 0.020 |
Why?
|
| Echocardiography | 1 | 2011 | 1054 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2006 | 57 | 0.020 |
Why?
|
| Receptors, Chemokine | 1 | 2006 | 44 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 2006 | 41 | 0.020 |
Why?
|
| CD28 Antigens | 1 | 2006 | 81 | 0.020 |
Why?
|
| Benzamides | 1 | 2006 | 109 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2006 | 142 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2006 | 171 | 0.010 |
Why?
|
| Gene Expression | 2 | 1999 | 1561 | 0.010 |
Why?
|
| Piperazines | 1 | 2006 | 240 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 1254 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 1064 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 1460 | 0.010 |
Why?
|
| Linear Models | 1 | 2006 | 683 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 417 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2006 | 370 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2006 | 373 | 0.010 |
Why?
|
| Acute Disease | 1 | 2006 | 1110 | 0.010 |
Why?
|
| Leukemia | 1 | 2006 | 371 | 0.010 |
Why?
|
| Electron Transport | 1 | 2001 | 55 | 0.010 |
Why?
|
| Sperm Count | 1 | 2001 | 79 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2001 | 261 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 6333 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2001 | 395 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 391 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3572 | 0.010 |
Why?
|
| Electron Transport Complex IV | 1 | 1999 | 39 | 0.010 |
Why?
|
| Yeasts | 1 | 1999 | 43 | 0.010 |
Why?
|
| Eukaryotic Cells | 1 | 1999 | 32 | 0.010 |
Why?
|
| Lipid Bilayers | 1 | 1999 | 48 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 4262 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 1999 | 63 | 0.010 |
Why?
|
| NAD | 1 | 1999 | 45 | 0.010 |
Why?
|
| Permeability | 1 | 1999 | 125 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1998 | 121 | 0.010 |
Why?
|
| Gene Targeting | 1 | 1999 | 177 | 0.010 |
Why?
|
| Ion Channel Gating | 1 | 1999 | 122 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1999 | 271 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1999 | 305 | 0.010 |
Why?
|
| Liposomes | 1 | 1999 | 188 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2001 | 760 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1999 | 443 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1998 | 144 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1998 | 457 | 0.010 |
Why?
|
| Introns | 1 | 1998 | 300 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 1201 | 0.010 |
Why?
|
| Testis | 1 | 1999 | 410 | 0.010 |
Why?
|
| COS Cells | 1 | 1996 | 275 | 0.010 |
Why?
|
| RNA | 1 | 1999 | 570 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 8209 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 658 | 0.010 |
Why?
|